Cargando…
Inflammatory Pathways and Their Implications in Heart Failure With Preserved Ejection Fraction
Autores principales: | Segar, Matthew W., Coulter, Stephanie A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Texas Heart® Institute, Houston
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658135/ https://www.ncbi.nlm.nih.gov/pubmed/37867309 http://dx.doi.org/10.14503/THIJ-23-8223 |
Ejemplares similares
-
Microvascular Rarefaction and Heart Failure With Preserved Ejection Fraction
por: Zeng, Heng, et al.
Publicado: (2019) -
The CardiAMP Cell Therapy for Heart Failure trial
por: Pepine, Carl J., et al.
Publicado: (2023) -
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction
por: Kaye, David M., et al.
Publicado: (2019) -
Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
por: Graziani, Francesca, et al.
Publicado: (2021) -
Hippo Pathway Knockdown Gene Therapy in the Heart
por: Heallen, Todd R., et al.
Publicado: (2023)